Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 187, Issue 1, Pages 149-153Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/346159
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [Z01SC006737] Funding Source: NIH RePORTER
- NCI NIH HHS [N01-CO-12400] Funding Source: Medline
Ask authors/readers for more resources
A clinical trial was conducted to test the activity of cidofovir (CDV), a drug with in vitro activity against Kaposi sarcoma (KS)-associated herpesvirus (KSHV), in KS. Five patients with human immunodeficiency virus-associated KS (4 receiving antiretroviral therapy) and 2 patients with classical KS were administered CDV (5 mg/kg/dose) weekly for 2 weeks and then every other week. All 7 patients had progression of their KS at a median of 8.1 weeks (range, 5-27 weeks). Skin biopsy specimens of KS lesions showed no change in expression of latent or early lytic genes, but, in the 1 assessable patient, there was decreased expression of a late lytic gene. There was no decrease in the virus load of KSHV in peripheral blood mononuclear cells. This study does not provide proof of principle for the treatment of KS with CDV. However, it remains possible that antiherpesvirus therapy can be developed for herpes-induced tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available